FGFR pathway inhibition enhances PD-1 blockade and modulates antitumor immunity in colorectal cancer models
Zhou Shang, Changqing Jing, Jiyuan Liu, Baolin Zhang, Marta Rúbies Bedós, Irineos Papakyriacou, Yumeng Mao, Yuezhi Chen · 2026
Read FGFR pathway inhibition enhances PD-1 blockade and modulates antitumor immunity in colorectal cancer models by Zhou Shang, Changqing Jing, Jiyuan Liu, Baolin Zhang, Marta Rúbies Bedós, Irineos Papakyriacou, Yumeng Mao, Yuezhi Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13670699.txt.
Description
Zhou Shang and co-authors test a drug pairing against colorectal cancer that usually shrugs off immunotherapy. Most colorectal tumors are microsatellite stable, and PD-1 blockade alone rarely helps them. The FGFR growth pathway helps tumors evade immune attack, so the team blocked it alongside PD-1.
In mouse tumor models and cell co-cultures, the pair cut T cell exhaustion. The treatment also pushed macrophages toward a tumor-fighting state, and gene profiling showed immune pathways switching on. Atlas data checked whether the same signals appear in human tumors. The results make FGFR blockade a candidate partner for immunotherapy in this stubborn cancer.
Catalog record
| CREATOR | Zhou Shang, Changqing Jing, Jiyuan Liu, Baolin Zhang, Marta Rúbies Bedós, Irineos Papakyriacou, Yumeng Mao, Yuezhi Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |